|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1992
|
|
gptkbp:atccode
|
N05 CF01
|
|
gptkbp:brand
|
gptkb:Ambien
|
|
gptkbp:chemical_formula
|
C19 H21 N3 O
|
|
gptkbp:class
|
sedative-hypnotic
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
sleep apnea
severe liver impairment
|
|
gptkbp:discovered_by
|
gptkb:Sandoz
|
|
gptkbp:dosage_form
|
5-10 mg
1.75 mg (sublingual)
6.25 mg (extended-release)
|
|
gptkbp:form
|
tablets
sublingual tablets
extended-release tablets
|
|
gptkbp:has_tradition
|
can develop with prolonged use
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
zolpidem
|
|
gptkbp:interacts_with
|
gptkb:CYP3_A4
|
|
gptkbp:legal_status
|
prescription-only
|
|
gptkbp:lifespan
|
2.5 hours
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:release_region
|
gptkb:Australia
gptkb:Brazil
gptkb:Canada
gptkb:France
gptkb:Germany
gptkb:India
gptkb:Japan
gptkb:South_Africa
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
drowsiness
|
|
gptkbp:suitable_for
|
gptkb:children
pregnant women
elderly patients
breastfeeding women
|
|
gptkbp:symptoms
|
anxiety
confusion
respiratory depression
tremors
hypotension
coma
rebound insomnia
|
|
gptkbp:used_for
|
insomnia
|
|
gptkbp:bfsParent
|
gptkb:Ambien
|
|
gptkbp:bfsLayer
|
6
|